<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998592</url>
  </required_header>
  <id_info>
    <org_study_id>EGA-01-IB</org_study_id>
    <nct_id>NCT03998592</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes</brief_title>
  <official_title>Phase I Clinical Trial for Assessment of Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InCor - Instituto do Coração - HCFMUSP.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BNDES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação Butantan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled phase I clinical trial with
      dose-escalation of a synthetic vaccine against Streptococcus pyogenes. The active component
      of this vaccine candidate is a synthetic polypeptide named StreptInCor designed to elicit
      humoral and cell-mediated immune responses. The vaccine will be formulated with Aluminium
      hydroxide in three different doses of StreptInCor (50 µg, 100µg, 200 µg). The proposed
      vaccination schedule is three doses (0, 1, 6 months). The doses will be escalated for the
      next group after safety review.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited and unsolicited adverse reactions</measure>
    <time_frame>Six months after last dose</time_frame>
    <description>Frequency of solicited and unsolicited adverse reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response to vaccine</measure>
    <time_frame>Six months after last dose</time_frame>
    <description>Rate of seroconversion for vaccine epitopes</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Rheumatic Fever</condition>
  <arm_group>
    <arm_group_label>Low-dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Streptococcus pyogenes vaccine (50 µg)</intervention_name>
    <description>Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant</description>
    <arm_group_label>Low-dose vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Streptococcus pyogenes vaccine (100 µg)</intervention_name>
    <description>Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant</description>
    <arm_group_label>Mid-dose vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Streptococcus pyogenes vaccine (200 µg)</intervention_name>
    <description>Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant</description>
    <arm_group_label>High-dose vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo without active component</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers, both sex, aging 18 to 45 years;

          -  Availability for all procedures during the study period;

          -  Provide free informed consent to join the study

        Exclusion Criteria:

          -  Diagnosis of concomitant infections or diseases that might affect immunity, including
             active HIV infection, hepatitis B, hepatitis C, diabetes mellitus, neoplasias, and
             autoimmune diseases;

          -  Previous or current diagnosis or family antecedent of rheumatic fever, chorea,
             obsessive-compulsive disorder or glomerulonephritis;

          -  Previous or current diagnosis of cardiac disease;

          -  Severe asma or Chronic obstructive pulmonary disease (COPD);

          -  Abnormal neurological clinical assessment, particularly chorea;

          -  Use of treatments that might affect the immunity in the last four weeks, including
             immunomodulators, corticosteroids (only systemic use equal or longer than two weeks),
             or antineoplastic agents;

          -  Use of treatments that might affect heart valves in the latest four weeks, including
             fenfluramine e dexfenfluramine;

          -  Kidney failure determined by creatinine clearance lower than 45 ml/min/1,73m²;

          -  History of intolerance or allergy to any component of investigational products,
             including antigen or adjuvant;

          -  Presence of abnormalities in heart valves or heart anatomy defined by echocardiogram;

          -  Electrocardiogram disturbances;

          -  Presence of cross-reactive antibodies against human tissues (heart, kidney, cartilage,
             brain) in screening tests;

          -  Evidence or suspicion of recent infection due to S. pyogenes assessed by clinical
             symptoms and negative rapid test for Streptococcus;

          -  Pregnancy, breastfeeding mother or intention to became pregnant during the study
             period;

          -  Any other condition that might affect the study process according to the
             investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiza Guilherme, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Butantan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roney O Sampaio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Palacios, MD, PhD</last_name>
    <phone>551137232121</phone>
    <email>ricardo.palacios@butantan.gov.br</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>peptide</keyword>
  <keyword>Streptococcus pyogenes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

